Biocad infliximab
Infliximab biosimilar developed by Biocad, development code BCD-055. Reference product Remicade.
About Biocad infliximab
Biocad, the Russian developer, has held an Indian import permission for its infliximab since the end of 2019, covering the full range of arthritis, bowel and skin uses.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Trials behind this product
Comparative trials on ClinicalTrials.gov matched to Biocad infliximab by development code, brand or developer. Registry data, sponsor-entered.
| Candidate | Developer or sponsor | Reference product | Phase | Design | Registry status | Started | Primary completion | Registry record |
|---|---|---|---|---|---|---|---|---|
| BCD-055 | Biocad | Remicade | Phase 3 | Comparative efficacy | Completed | Jan 2016 | May 2017 | NCT02762812 |
| BCD-055 | Biocad | Remicade | Phase 3 | Comparative efficacy | Completed | Jan 2016 | Jul 2018 | NCT02762838 |
Other developers in the same markets
Where Biocad infliximab holds an approval, these are the other infliximab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 2 | Celltrion (Remsima / Inflectra), Reliance Life Sciences (Reliance Life Sciences infliximab) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Biocad: Biocad rituximab, Biocad trastuzumab.
Chronology
- CDSCODec 2019CDSCO permission granted
Sources
S013CDSCO, import and market permissions till 2019 (r-DNA) Primary (regulator)
Planning infliximab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant